Death (all causes) · people with CKD
It is very uncertain whether summary of findings: Lanthanum changes death (all causes) compared with placebo/usual care (very low certainty).
1 finding from 1 review
Death at 6 months · people with CKD
Uric acid lowering therapies (UAR) showed no clear difference in death at 6 months compared with placebo, no treatment or usual care (low certainty).
1 finding from 1 review
Death at 2 years · people with CKD
Uric acid lowering therapies (UAR) showed no clear difference in death at 2 years compared with placebo, no treatment or usual care (low certainty).
1 finding from 1 review
Dialysis · people with CKD
Uric acid lowering therapies (UAR) showed no clear difference in dialysis at 2 years compared with placebo, no treatment or usual care (low certainty).
1 finding from 1 review
Creatinine level · people with CKD
1 finding from 1 review
eGFR or creatinine clearance (mL/min/1.73m²) · people with CKD
1 finding from 1 review
Cardiovascular events · people with CKD
Uric acid lowering therapies (UAR) showed no clear difference in cardiovascular events compared with placebo, no treatment or usual care (low certainty).
1 finding from 1 review
Serum UA · people with CKD
1 finding from 1 review
Incidence of HCV infection (9 months) · patients requiring haemodialysis
It is very uncertain whether dialysis machine separation changes incidence of HCV infection (9 months) compared with usual care (very low certainty).
1 finding from 1 review
Incidence of HCV infection (18 months) · patients requiring haemodialysis
It is very uncertain whether dialysis machine separation changes incidence of HCV infection (18 months) compared with usual care (very low certainty).
1 finding from 1 review
Vertebral fracture by radiography · postmenopausal women with osteoporosis and CKD stages 3‐4
Any anti‐osteoporotic drugs may leads to lower vertebral fracture by radiography compared with placebo (low certainty).
1 finding from 1 review
Vertebral fracture by radiography · postmenopausal women with osteoporosis and CKD stages 5 and 5D
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical fracture · postmenopausal women with osteoporosis and CKD stages 5 and 5D
It is very uncertain whether raloxifene changes clinical fracture compared with placebo (very low certainty).
1 finding from 1 review
Mean change in BMD of the femoral neck · postmenopausal women with osteoporosis and CKD stages 5 and 5D
It is very uncertain whether raloxifene changes mean change in BMD of the femoral neck compared with placebo (very low certainty).
1 finding from 1 review
Mean change in BMD of the lumbar spine · postmenopausal women with osteoporosis and CKD stages 5 and 5D
Raloxifene may leads to higher mean change in BMD of the lumbar spine compared with placebo (low certainty).
1 finding from 1 review
Total hip BMD · postmenopausal women with osteoporosis and CKD stages 5 and 5D
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean change in BMD of the distal radius · postmenopausal women with osteoporosis and CKD stages 5 and 5D
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · postmenopausal women with osteoporosis and CKD stages 5 and 5D
1 finding from 1 review
Death · postmenopausal women with osteoporosis and CKD stages 5 and 5D
It is very uncertain whether raloxifene changes death compared with placebo (very low certainty).
1 finding from 1 review
QoL · postmenopausal women with osteoporosis and CKD stages 5 and 5D
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found